Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Primary Diffuse Leptomeningeal Melanocytosis, A Diagnoatic Conundrum
Neurol 101:e576-3580, Selvarajan,J.M.P.,et al, 2023
Five-Year Outcomes of PFO Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 384:970-971, , 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Tailoring the Approach to Embolic Stroke of Undetermined Source
JAMA Neurol 76:855-861, Kamel, H.,et al, 2019
Debate Sparks Over LATE, a Recently Recognized Dementia
JAMA 322:914-916, Abbasi, J., 2019
PFO Closure for Cryptogenic Stroke
NEJM 378:1639-1642, Mi, M.Y.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Cardiac Magnetic Resonance Imaging: A New Tool to Identify Cardioaortic Sources in Ischaemic Stroke
JNNP 88:31-37, Yaghi, S.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Hydrocephalus in Children
Lancet 387:788-799, Kahle, K.T.,et al, 2016
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Review of the Utility of Prophylactic Anticonvulsant Use in Critically Ill Patients with Intracerebral Hemorrhage
Stroke 47:2666-2672, Gilmore, E.J.,et al, 2016
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
An Index to Identify Stroke-Related vs Incidental Patent Foramen Ovale in Cryptogenic Stroke
Neurol 81:619-625,619, Kent, D.M.,et al, 2013
Patent Foramen Ovale and Cryptogenic Stroke
Stroke 44:2676-2678, Furlan, A.J. and Jauss, M., 2013
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Seizure risk with AVM Treatment or Conservative Management
Neurol 79:500-507, Josephson, C.B.,et al, 2012
Effectiveness of Adding Memantine to an Alzheimer Dementia Treatment Regimen Which Already Includes Stable Donepezil Therapy: A Critically Appraised Topic
The Neurologist 17:121-123, Riordan,K.C.,et al, 2011
Disclosure of APOE Genotype for Risk of Alzheimers Disease
NEJM 361:245-254,298, Green,R.C.,et al, 2009
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Dementia Screening in Primary Care: Is It Time?
JAMA 298:2409-2411, Brayne,C.,et al, 2007
Coxibs and Alzheimers Disease: Should They Stay or Should They Go?
Ann Neurol 59:219-228, Firuzi,O. &Pratico,D., 2006
The First Seizure and Its Management in Adults and Children
BMJ 332:339-342, Pohlmann-Eden,B.,et al, 2006
Donepezil in Patients with Severe Alzheimers Disease: Double-Blind, Parallel-Group, Placebo-Controlled Study
Lancet 367:1057-1065,1031, Winblad,B.,et al, 2006
Transient Global Amnesia: Increasing Evidence of a Venous Etiology
Arch Neurol 63:1334-1336 ,1336, Menendez,M. &Rivera,M.M., 2006
Cerebral Aneurysms
NEJM 355:928-939, Brisman,J.L.,et al, 2006
Simultaneous Carotid Endarterectomy and Coronary Artery Bypass Surgery in Canada
Neurol 64:1435-1437,1332, Hill,M.D.,et al, 2005
Patent Foramen Ovale Closure Devices
JAMA 294:366-369, Maisel,W.H.&Laskey,W.K., 2005
Cholinesterase Inhibitors for Patients with Alzheimers Disease: Systematic Review of Randomised Clinical Trials
BMJ 331:321-323, Kaduszkiewicz,H.,et al, 2005
Patent Foramen Ovale in Young Adults with Unexplained Stroke
NEJM 353:2361-2372, Kizer,J.R. &Devereux,R.B., 2005
Long-term Donepezil Treatment in 565 Patients with Alzheimer's Disease (AD2000): Randomised Double-Blind Trial
Lancet 363:2105-2115,2100, AD2000 Collaborative Group, 2004
Management of Acute Optic Neuritis
Lancet 360:1953-1962, Hickman,S.J.,et al, 2002
Atrial Fibrillation and Stroke
Stroke 32:803-808, Hart,R.G. &Halperin,J.L., 2001
Intraspinal Steroids: History, Efficacy, Accidentality, and Controversy with Review of United States Food and Drug Administration Reports
JNNP 70:433-443, Nelson,D.A. & Landau,W.M., 2001
Brainstem Gliomas in Adults: Prognostic Factors and Classification
Brain 124:2528-2539, Guillamo,J.-S.,et al, 2001
Trauma Does Not Precipitate Multiple Sclerosis
Arch Neurol 57:1077-1078, Cook.S.D., 2000
Trauma to the Central Nervous System May Result in Formation or Enlargement of Multiple Sclerosis Plaques
Arch Neurol 57:1074-1076,1078, Poser,C.M., 2000
Do We Have Drugs for Dementia? No
Arch Neurol 56:735-737, Pryse-Phillips,W., 1999
Do We Have a Treatment for Alzheimer Disease? Yes
Arch Neurol 56:738-739,735, Gauthier,S., 1999
Is Cholesterol a Risk Factor for Stroke? No
Arch Neurol 56:1521-1524, Landau,W.M., 1999
Is Cholesterol a Risk Factor for Stroke? Yes
Arch Neurol 56:1518-1520,1524, Demchuk,A.M.,et al, 1999